QUALCOMM, Inc. vs Zimmer Biomet Holdings Inc — how do they compare? QUALCOMM, Inc. trades at $177.44 (market cap $182.87B), while Zimmer Biomet Holdings Inc trades at $88.69 (market cap $17.20B). The key difference: QUALCOMM, Inc. is far larger — about 10.6× Zimmer Biomet Holdings Inc's market cap, and QUALCOMM, Inc. pays the higher dividend (2.12%). Which is the better fit depends on your goals.
| QCOM | ZBH | |
|---|---|---|
Market Cap | $182.87B | $17.20B |
Sector | Technology | Health |
52-Week High | $251.10 | $107.71 |
52-Week Low | $124.07 | $79.58 |
Enterprise Value | $188.34B | $24.25B |
Dividend Yield | 2.12% | 1.08% |
Signals from Pluang's Aura AI — not financial advice
Qualcomm (QCOM) trades at $170.32, down 0.85% with bearish technical signals despite recent earnings beats. The stock shows strong fundamentals with 22.31% net margins and 29.27% ROE, though facing margin pressures and smartphone market headwinds. Recent news highlights AI diversification efforts through automotive and data center markets, with CEO Cristiano Amon projecting 'multiple billions' in data center revenue ahead.
Outlook remains mixed with 42.65% analyst buy ratings and $228.22 consensus target suggesting 34% upside, but technical weakness and competitive threats from Nvidia's PC chip entry create near-term uncertainty. Key risks include smartphone demand softness and margin compression, while AI expansion provides long-term growth potential.
Zimmer Biomet (ZBH) trades at $88.92, down 2.41% on the day, with a bearish technical signal but strong fundamentals including a 70.03% gross margin and three consecutive quarterly EPS beats. Revenue grew to $8.23B in 2025, though net income margin compressed to 8.56%. The company announced a $1 billion share repurchase increase and expansion in India, while maintaining a dividend.
The stock offers a 10% upside to the $97.67 consensus price target, supported by value metrics and operational strength, but faces risks from rising debt levels and competitive pressures. Analyst sentiment is mixed with 40% buy ratings, suggesting cautious optimism amid near-term technical weakness.
Trailing returns across standard periods
Latest headlines on both assets
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →